Thanks to their safety and multifaceted mechanisms to diverse range of diseases,
GNT Pharma's drug candidates have a high chance of success in clinical trials.
NELONEMDAZ Nelonemdaz / Drug for stroke
A new synthetic drug dually targeting two drivers of neuronal cell death after stroke: gutamate-mediated neurotoxicity and reactive oxygen species (ROS).MORE VIEW
CRISDESALAZINE Crisdesalazine / Drug for Alzheimer’s disease (AD)
A new synthetic drug dually targeting two drivers of neurodegenerative diseases such as AD: inflammation and reactive oxygen species (ROS).MORE VIEW
FLUSALAZINE Flusalazine / Drug for inflammatory - respiratory diseases and pain
A next-generation, new synthetic drug for inflammatory - respiratory diseases and pain that drastically reduces gastrointestinal and cardiovascular side effects of pre-existing anti-inflammatory analgesic drugs.MORE VIEW